Impact of adjuvant chemotherapy in the long‐term outcome of patients with resected gastric cancer

Abstract

After curative surgery, adjuvant chemotherapy with mitomycin C, both alone or combined with Tegafur, improved the long-term cure rate over no postoperative chemotherapy in locally advanced gastric cancer patients. This benefit was not influenced by other prognostic factors.

Gastric cancer confined to the muscularis propria: A possible candidate for laparoscopic surgery or adjuvant therapy

“…Until recently, attempts at preventing recurrence, usually using adjuvant chemotherapy, have been ineffective, although Grau et al [2] presented a retrospective study demonstrating the improvement in the long-term cure rate of adjuvant chemotherapy over that of no postoperative chemotherapy. Macdonald [3] reported on the results of a large United States Intergroup study, which showed that combined chemoradiation, following gastric resection, improves the median time to relapse and overall survival, with adjuvant chemotherapy alone being of minimal benefit.…”

“…Laparoscopic gastric surgical procedures have been found to be safe and feasible for early gastric cancer (EGC) and submucosal tumors [1]. On the other hand, adjuvant therapy, including chemotherapy alone or combined chemoradiation following gastric resection for advanced gastric cancer, has been reported to improve the median time to relapse and overall survival in selected patients [2,3].…”

Long term survival of patients with gastric cancer treated with adjuvant radio-chemotherapy: proposal of a prognostic index with implication for treatment modification

“…Although perioperative chemotherapy [10] or adjuvant chemotherapy [15] alone (popular in Asia) have been shown to increase survival in addition to definitive surgery, adjuvant radiochemotherapy is still the common standard of care in the United States. Adjuvant radiochemotherapy is sometimes a more practical or better solution for patients with certain demography such as those who are operated by surgeons from community hospitals.…”

The Effect of Locoregional Transarterial Infusion Chemotherapy on Liver Metastasis after Gastric Cancer Resection

“…24 Numerous randomized studies of adjuvant chemotherapy in gastric cancer have been performed, some of which have reported an overall survival benefit; 11,25 others have failed to show any such advantage. 13,26 There is no consensus on the role of adjuvant intraperitoneal chemotherapy because a consistent overall survival benefit has not been demonstrated in randomized trials. 3 The present retrospective study investigated the effect of adjuvant TAI chemotherapy and TACE on liver metastatic gastric adenocarcinoma, and showed that TAI chemotherapy was more effective in preventing liver metastasis than systemic chemotherapy.…”